Vasoactive intestinal peptide and the stimulation of lactotroph growth by oestradiol in rats.

Prysor-Jones RA, Silverlight JJ, Kennedy SJ, Jenkins JS

The Journal of endocrinology1 Feb 1988Cited by 18 (Europe PMC)

PMID3351421DOI10.1677/joe.0.1160259PepBankPUB-03351421

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Natural levels measured5

These results measure the body's own peptide. Nobody was given the peptide. They are not evidence about taking it. They are left out of key results, evidence counts and charts.

01AnimalEndogenous levelAnimal study (in vivo)Mechanism
In female rats treated with oestradiol, the concentration of the body's own VIP in the pituitary increased.
In plain wordsIn rats treated with oestradiol, the body's own VIP concentration in the pituitary went up.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasePituitary VIP concentration after oestradiol
Study
ratn: not reported in source
Female rats treated with oestradiol
Outcome group
Endogenous peptide levels · Endocrine and hormones
Source sentences
Summary
The concentration of VIP in the pituitary was increased by oestradiol treatment but decreased in the non-median eminence hypothalamus.
1 context sentence(design, population, supporting numbers)
Summary · context
Treatment with a high dose of oestradiol for 6 months caused hyperprolactinaemia and pituitary hyperplasia in female Wistar-Furth rats.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0335142101
02AnimalEndogenous levelAnimal study (in vivo)Mechanism
In female rats treated with oestradiol, the concentration of the body's own VIP in the non-median eminence hypothalamus decreased.
In plain wordsIn rats treated with oestradiol, the body's own VIP concentration in part of the hypothalamus went down.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
DecreaseNon-median eminence hypothalamus VIP concentration after oestradiol
Study
ratn: not reported in source
Female rats treated with oestradiol
Outcome group
Endogenous peptide levels · Endocrine and hormones
Source sentences
Summary
The concentration of VIP in the pituitary was increased by oestradiol treatment but decreased in the non-median eminence hypothalamus.
1 context sentence(design, population, supporting numbers)
Summary · context
Treatment with a high dose of oestradiol for 6 months caused hyperprolactinaemia and pituitary hyperplasia in female Wistar-Furth rats.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0335142102
03AnimalEndogenous levelAnimal study (in vivo)Mechanism
In rats treated with oestradiol, the content of the body's own VIP in the median eminence increased.
In plain wordsIn rats treated with oestradiol, the body's own VIP content in the median eminence went up.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreaseMedian eminence VIP content after oestradiol
Study
ratn: not reported in source
Female rats treated with oestradiol
Outcome group
Endogenous peptide levels · Endocrine and hormones
Source sentences
Summary
In the median eminence the VIP content was increased by oestradiol treatment
1 context sentence(design, population, supporting numbers)
Summary · context
Treatment with a high dose of oestradiol for 6 months caused hyperprolactinaemia and pituitary hyperplasia in female Wistar-Furth rats.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0335142103
04AnimalEndogenous levelAnimal study (in vivo)Other
In rats treated with both oestradiol and fluphenazine, median eminence VIP content correlated positively and significantly with pituitary wet weight.
In plain wordsIn rats given oestradiol and fluphenazine, more of the body's own VIP in the median eminence was linked to a heavier pituitary.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableCorrelation of median eminence VIP with pituitary wet weight
Study
ratn: not reported in source
Female rats treated with oestradiol
Outcome group
Endogenous peptide levels · Endocrine and hormones
Source sentences
Summary
the amount present correlated positively and significantly with pituitary wet weight in animals treated with both oestradiol and fluphenazine.
1 context sentence(design, population, supporting numbers)
Summary · context
Treatment with a high dose of oestradiol for 6 months caused hyperprolactinaemia and pituitary hyperplasia in female Wistar-Furth rats.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0335142104
05AnimalEndogenous levelAnimal study (in vivo)Mechanism
In Fischer 344 rats, oestradiol raised the pituitary concentration of the body's own VIP five times more than in Wistar controls.
In plain wordsIn Fischer 344 rats, oestradiol raised the body's own VIP in the pituitary five times more than in Wistar rats.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
IncreasePituitary VIP concentration after oestradiol in Fischer 344 versus Wistar rats
Study
ratn: not reported in source
Fischer 344 rats treated with oestradiol
Comparator
Wistar controls
Outcome group
Endogenous peptide levels · Endocrine and hormones
Source sentences
Summary
In Fischer 344 rats, oestradiol produced greater incremental changes in pituitary wet weight and plasma concentrations of prolactin than in Wistar controls and the increase in the pituitary concentration of VIP was five times greater.
1 context sentence(design, population, supporting numbers)
Summary · context
Treatment with a high dose of oestradiol for 6 months caused hyperprolactinaemia and pituitary hyperplasia in female Wistar-Furth rats.
This result measures the body's own Vasoactive intestinal peptide (VIP, aviptadil). Nobody was given the peptide. It is not evidence about taking it.
Report a problemFND-0335142105

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:58 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.